Buscar
01/07/2026
Local control in oligometastatic cancer patients following metastasis-directed stereotactic ablative radiotherapy: An interim analysis of ESTRO EORTC E2-RADIatE OligoCare cohort
Joye, I, Ricardi, U, Scorsetti, M, Alongi, F, Greto, D, Christ, SM, Braam, P, Simek, IM, Secerov-Ermenc, A, Lievens, Y, Jereczek-Fossa, BA, Dirix, P, Stellamans, K, Ramella, S, Peulen, H, Sancho-Pardo, G, Salinas, JR, Sirak, I, Jeene, P, Bral, S, Benavente, S, Hemmatazad, H, Elaut, N, Clementel, E, Oppong, FB, Guckenberger, M, Ost, P. Local control in oligometastatic cancer patients following metastasis-directed stereotactic ablative radiotherapy: An interim analysis of ESTRO EORTC E2-RADIatE OligoCare cohort. RADIOTHERAPY AND ONCOLOGY. 2026; 220DOI:10.1016/j.radonc.2026.111545. PMID:42019680. IF:5.300(Q1/2D).
01/07/2026
Patient-Level Persistence of On-Treatment Remission With Guselkumab: Pooled Results From VOYAGE 1 and VOYAGE 2 Participants With Moderate-to-Severe Plaque Psoriasis
Tada, Y, Foley, P, Armstrong, AW, Merola, JF, Chang, JS, Fakharzadeh, S, Rampakakis, E, Huang, YH, Puig, L, Langley, RG. Patient-Level Persistence of On-Treatment Remission With Guselkumab: Pooled Results From VOYAGE 1 and VOYAGE 2 Participants With Moderate-to-Severe Plaque Psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2026; 95(1)DOI:. PMID:. IF:11.800(Q1/1D).
01/07/2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity A Phase 3b Randomized Clinical Trial
Lebwohl, M, Blauvelt, A, Kartman, CE, Leatherwood, C, Gordon, KB, Sattar, N, Puig, L, Merola, JF, Siu, K, Wang, R, Sun, L, Leung, A, Somani, N, Rueda, MJ, Cardoso, A, Genovese, MC, Armstrong, AW, Strober, B. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity A Phase 3b Randomized Clinical Trial. JAMA Dermatology. 2026; 162(7)DOI:10.1001/jamadermatol.2026.1753. PMID:42139049. IF:11.000(Q1/1D).
01/07/2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease
Puig, L, Tsai, TF, Soriano, ER, Bhutani, T, Miller, M, Kollmeier, AP, Li, S, Li, HW, Ofori, S, Pawlikowski, J, Adamson, E, Gooderham, M, Garcia, AL, Lebwohl, M, Nash, P. Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease. JOURNAL OF DERMATOLOGY. 2026; 53(7)DOI:10.1111/1346-8138.70314. PMID:42226468. IF:2.700(Q2/4D).
01/07/2026
Management of Patients Diagnosed with Endometrial Hyperplasia: Comparison of Guidelines
Restaino, S, Paglietti, C, Paparcura, F, Giorgio, B, Andrea, CV, Catena, U, Raffone, A, Orsaria, M, Ronsini, C, Scibilia, G, Simoncini, T, Raimondo, D, Di Donato, V, Elhadi, M, Capobianco, G, Negre, RR, Biasioli, A, Martina, MD, Laura, M, Uccella, S, Ciavattini, A, Zupi, E, Seracchioli, R, Driul, L, Scollo, P, Perrone, AM, Iaco, PD, Arcieri, M, Fanfani, F, Vizzielli, G. Management of Patients Diagnosed with Endometrial Hyperplasia: Comparison of Guidelines. Cancers. 2026; 18(13)DOI:10.3390/cancers18132048. PMID:42449594. IF:4.400(Q2/3D).
01/07/2026
Medication reconciliation in critically ill patients: digital innovation for patient safety
Cerezuela, MM, Tomás, LPD, Ramos, JR, Pinto, AD, Chiva, ED, Rubio, MV, González, IA, Fernández, CB, Moral, LD, Lugea, AE, García, MAA, García, TB, Sacristán, SC, Fernández, MA, Pérez, SO, Moreno, FB. Medication reconciliation in critically ill patients: digital innovation for patient safety. Enfermeria Intensiva. 2026; 37(3)DOI:10.1016/j.enfi.2026.500615. PMID:. IF:(Q/D).